WallStreetZenWallStreetZen

NASDAQ: GLYC
Glycomimetics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GLYC stock forecasts and price targets.

Forecast return on equity

Is GLYC forecast to generate an efficient return?

Company
-48.57%
Industry
142.9%
Market
80.27%
GLYC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GLYC forecast to generate an efficient return on assets?

Company
-23.27%
Industry
35.65%
GLYC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GLYC earnings per share forecast

What is GLYC's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.05
Avg 2 year Forecast
-$0.08
Avg 3 year Forecast
-$0.07

GLYC revenue forecast

What is GLYC's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$3.8M
Avg 2 year Forecast
$9.6M
Avg 3 year Forecast
$40.4M

GLYC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLYC$0.25N/AN/A
AFMD$1.00$9.67+871.56%Buy
EDSA$2.33$21.00+801.29%Buy
BCTX$4.46$32.00+617.49%Buy
CING$4.21$30.67+628.43%Strong Buy
View Top Biotech Stocks

Glycomimetics Stock Forecast FAQ

What is GLYC's earnings growth forecast for 2025-2027?

(NASDAQ: GLYC) Glycomimetics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Glycomimetics's earnings in 2025 is -$37,879,158.On average, 2 Wall Street analysts forecast GLYC's earnings for 2025 to be -$3,225,693, with the lowest GLYC earnings forecast at -$5,161,109, and the highest GLYC earnings forecast at -$1,290,277. On average, 1 Wall Street analyst forecast GLYC's earnings for 2026 to be -$5,161,109, with the lowest GLYC earnings forecast at -$5,161,109, and the highest GLYC earnings forecast at -$5,161,109.

In 2027, GLYC is forecast to generate -$4,515,970 in earnings, with the lowest earnings forecast at -$4,515,970 and the highest earnings forecast at -$4,515,970.

If you're new to stock investing, here's how to buy Glycomimetics stock.

What is GLYC's revenue growth forecast for 2026-2028?

(NASDAQ: GLYC) Glycomimetics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Glycomimetics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast GLYC's revenue for 2026 to be $245,152,676, with the lowest GLYC revenue forecast at $245,152,676, and the highest GLYC revenue forecast at $245,152,676. On average, 2 Wall Street analysts forecast GLYC's revenue for 2027 to be $618,365,367, with the lowest GLYC revenue forecast at $522,562,282, and the highest GLYC revenue forecast at $714,168,452.

In 2028, GLYC is forecast to generate $2,606,360,025 in revenue, with the lowest revenue forecast at $1,387,048,033 and the highest revenue forecast at $3,825,672,017.

What is GLYC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: GLYC) forecast ROA is -23.27%, which is lower than the forecast US Biotechnology industry average of 35.65%.

What is GLYC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: GLYC) Glycomimetics's current Earnings Per Share (EPS) is -$0.59. On average, analysts forecast that GLYC's EPS will be -$0.05 for 2025, with the lowest EPS forecast at -$0.08, and the highest EPS forecast at -$0.02. On average, analysts forecast that GLYC's EPS will be -$0.08 for 2026, with the lowest EPS forecast at -$0.08, and the highest EPS forecast at -$0.08. In 2027, GLYC's EPS is forecast to hit -$0.07 (min: -$0.07, max: -$0.07).

What is GLYC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: GLYC) forecast ROE is -48.57%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.